Related references
Note: Only part of the references are listed.Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Darrell D. Mousseau et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
Type A and B Monoamine Oxidase in Age-Related Neurodegenerative Disorders: Their Distinct Roles in Neuronal Death and Survival
Makoto Naoi et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors
Spyros N. Deftereos et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2012)
Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
Peter Jenner et al.
MOVEMENT DISORDERS (2011)
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
Jack J. Chen et al.
CLINICAL THERAPEUTICS (2007)
Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease
Peter Riederer et al.
PARKINSONISM & RELATED DISORDERS (2007)
Clinical applications of MAO-inhibitors
P Riederer et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Share Paper
